Advances in treating insomnia

Kumar Budur, MD
Sleep Disorders Center, The Neuroscience Institute, Cleveland Clinic

Carlos Rodriguez, MD
Sleep Disorders Center, The Neuroscience Institute, Cleveland Clinic

Nancy Foldvary-Schaefer, DO
Director and Section Head, Sleep Disorders Center; The Neuroscience Institute; and Women’s Health Center, Cleveland Clinic

Address: Kumar Budur, MD, Cleveland Clinic Sleep Disorders Center, FA20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Dr. Budur has indicated that he has received honoraria from Takeda Pharmaceuticals. Dr. Foldvary-Schaefer has indicated that she has received honoraria and consulting fees from GlaxoSmithKline and honoraria from UCB corporation.

Kumar Budur, MD
Sleep Disorders Center, The Neuroscience Institute, Cleveland Clinic

Carlos Rodriguez, MD
Sleep Disorders Center, The Neuroscience Institute, Cleveland Clinic

Nancy Foldvary-Schaefer, DO
Director and Section Head, Sleep Disorders Center; The Neuroscience Institute; and Women’s Health Center, Cleveland Clinic

Address: Kumar Budur, MD, Cleveland Clinic Sleep Disorders Center, FA20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Dr. Budur has indicated that he has received honoraria from Takeda Pharmaceuticals. Dr. Foldvary-Schaefer has indicated that she has received honoraria and consulting fees from GlaxoSmithKline and honoraria from UCB corporation.

Kumar Budur, MD
Sleep Disorders Center, The Neuroscience Institute, Cleveland Clinic

Carlos Rodriguez, MD
Sleep Disorders Center, The Neuroscience Institute, Cleveland Clinic

Nancy Foldvary-Schaefer, DO
Director and Section Head, Sleep Disorders Center; The Neuroscience Institute; and Women’s Health Center, Cleveland Clinic

Address: Kumar Budur, MD, Cleveland Clinic Sleep Disorders Center, FA20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Dr. Budur has indicated that he has received honoraria from Takeda Pharmaceuticals. Dr. Foldvary-Schaefer has indicated that she has received honoraria and consulting fees from GlaxoSmithKline and honoraria from UCB corporation.